Cargando…
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Via Medica
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890419/ https://www.ncbi.nlm.nih.gov/pubmed/34787891 http://dx.doi.org/10.5603/CJ.a2021.0148 |
| _version_ | 1784661634693726208 |
|---|---|
| author | Kubica, Jacek Podhajski, Przemysław Magielski, Przemysław Kubica, Aldona Adamski, Piotr Junik, Roman Pinkas, Jarosław Navarese, Eliano P. |
| author_facet | Kubica, Jacek Podhajski, Przemysław Magielski, Przemysław Kubica, Aldona Adamski, Piotr Junik, Roman Pinkas, Jarosław Navarese, Eliano P. |
| author_sort | Kubica, Jacek |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8890419 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Via Medica |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88904192022-03-03 IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study Kubica, Jacek Podhajski, Przemysław Magielski, Przemysław Kubica, Aldona Adamski, Piotr Junik, Roman Pinkas, Jarosław Navarese, Eliano P. Cardiol J Covid-19 Via Medica 2022-02-23 /pmc/articles/PMC8890419/ /pubmed/34787891 http://dx.doi.org/10.5603/CJ.a2021.0148 Text en Copyright © 2022 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially |
| spellingShingle | Covid-19 Kubica, Jacek Podhajski, Przemysław Magielski, Przemysław Kubica, Aldona Adamski, Piotr Junik, Roman Pinkas, Jarosław Navarese, Eliano P. IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title_full | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title_fullStr | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title_full_unstemmed | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title_short | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study |
| title_sort | impact of pcsk9 inhibition on clinical outcome in patients during the inflammatory stage of the sars-cov-2 infection: rationale and protocol of the impact-sirio 5 study |
| topic | Covid-19 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890419/ https://www.ncbi.nlm.nih.gov/pubmed/34787891 http://dx.doi.org/10.5603/CJ.a2021.0148 |
| work_keys_str_mv | AT kubicajacek impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT podhajskiprzemysław impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT magielskiprzemysław impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT kubicaaldona impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT adamskipiotr impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT junikroman impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT pinkasjarosław impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study AT navareseelianop impactofpcsk9inhibitiononclinicaloutcomeinpatientsduringtheinflammatorystageofthesarscov2infectionrationaleandprotocoloftheimpactsirio5study |